Our Clinical Partners

Pharmacy

The CommonSpirit Pharmacy Enterprise is dedicated to improving medication-related patient outcomes, providing high-quality, safe, and cost-effective medication management. Over the past year, the national pharmacy team undertook several research and data development projects to enhance patient care and financial improvements. Our team members took on leadership roles in these projects, collaborating with internal and external partners to improve medication-related outcomes.

Research Highlights

Completed an IRB-approved real-world data study:

Our team completed a study of Remdesivir in COVID-19 patients measuring length of stay and clinical outcomes. The study demonstrated that Remdesivir patients were more likely to have a longer length of hospitalization without any difference in clinical improvement.

Analyzed medication expense patterns:

Our team created dashboards to drive change toward more pharmacoeconomic biosimilar medications and to drive clinical initiatives to help exceed FY23 value capture goals. Fiscal year to date, the Pharmacy Enterprise has realized more than $40 million in savings.

Collaborated to develop pharmacy-led separately reimbursable infusion analytics:

Our team, in collaboration with payor strategy, is in the second phase of creating a mechanism to monitor separately reimbursable medications’ cost, margin and reimbursement opportunities. The ultimate goal is to improve the reimbursement processes to ensure correct payments for the medications administered so we can continue to provide excellent care.

Developing a drug shortage monitoring system:

In collaboration with the application development team, a bot is being developed to provide early detection of potential drug shortages. This will provide a mechanism to be proactive in ensuring we can provide the best care possible.